American Heart Journal
Volume 157, Issue 2 , Pages 352-360.e2 , February 2009

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

  • Daniel Bloomfield, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • Corresponding Author InformationReprint requests: Daniel Bloomfield, MD, Merck Research Laboratories, 126 East Lincoln Avenue, RY34-A218, Rahway, NJ 07065-0900.
    • ,
  • Gary L. Carlson, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Aditi Sapre, PhD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Diane Tribble, PhD

      Affiliations

    • Isis Pharmaceuticals, Carlsbad, CA
    • ,
  • James M. McKenney, Pharm D

      Affiliations

    • Virginia Commonwealth University and National Clinical Research, Inc, Richmond, VA
    • ,
  • Thomas W. Littlejohn III, MD

      Affiliations

    • Piedmont Medical Research, Winston-Salem, NC
    • ,
  • Christine McCrary Sisk, BS

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Yale Mitchel, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ
    • ,
  • Richard C. Pasternak, MD

      Affiliations

    • Merck Research Laboratories, Rahway, NJ

Received 9 June 2008 ,Accepted 26 September 2008.

  • Image Result

    Study design.

    Study design.

  • Image Result

    Changes from baseline in LDL-C over time: A, anacetrapib monotherapy versus placebo and B, anacetrapib + atorvastatin 20 versus atorvastatin 20 mg.

    Changes from baseline in LDL-C over time: A, anacetrapib monotherapy versus placebo and B, anacetrapib + atorvastatin 20 versus atorvastatin 20 mg.

  • Image Result

    Changes from baseline in HDL-C over time: A, anacetrapib monotherapy versus placebo and B, anacetrapib + atorvastatin 20 versus atorvastatin 20 mg.

    Changes from baseline in HDL-C over time: A, anacetrapib monotherapy versus placebo and B, anacetrapib + atorvastatin 20 versus atorvastatin 20 mg.

  • Image Result

    Changes from baseline in LDL-C for patients with triglycerides above and below the median.

    Changes from baseline in LDL-C for patients with triglycerides above and below the median.

  • Image Result

    Changes from baseline in A, apo E and B, Lp(a).

    Changes from baseline in A, apo E and B, Lp(a).

  • Image Result

    Changes from baseline in systolic and diastolic blood pressure at week 8 with anacetrapib monotherapy versus placebo.

    Changes from baseline in systolic and diastolic blood pressure at week 8 with anacetrapib monotherapy versus placebo.

 Registered Clinical Trial No.: NCT00325455.

PII: S0002-8703(08)00828-4

doi: 10.1016/j.ahj.2008.09.022

American Heart Journal
Volume 157, Issue 2 , Pages 352-360.e2 , February 2009

Article Tools

* Image Usage & Resolution